NUVLConference•prnewswire•
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Sentiment:Negative (20)
Summary
CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 28, 2025 by prnewswire